Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...

Sarepta Therapeutics has rejected a call by the Food and Drug Administration to stop shipments of its muscular dystrophy drug.

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

Shares of Sarepta Therapeutics plummeted Friday following a report that a third patient has died during a clinical trial for ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Although Sarepta initially appeared to have avoided the worst possible outcome for Elevidys—market withdrawal—thanks to the gene therapy’s new black box warning, the FDA is signaling stronger ...

Throughout the last three months, 12 analysts have evaluated Sarepta Therapeutics (NASDAQ:SRPT), offering a diverse set of opinions from bullish to bearish.The table below provides a concise ...

9 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Across the recent three months, 26 analysts have shared their insights on Sarepta Therapeutics (NASDAQ: SRPT), expressing a variety of opinions spanning from bullish to bearish. The table below ...